Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818086 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04818086 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 18 participants.
The verdict
NCT04818086, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
Interventions
- DRUG Placebo
- DRUG Lemborexant
- DRUG Buprenorphine-naloxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2023-04-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818086
The ClinicalTrials.gov registry entry for NCT04818086 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04818086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04818086 about?
NCT04818086 is a clinical study titled "Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder". The purpose of this research study is to test the safety, tolerability, drug interactions with buprenorphine-naloxone, and effectiveness lemborexant when used to treat Opioid Use Disorder.
What is the current status of trial NCT04818086?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-05-03. Estimated completion is 2023-04-20.
What interventions are being tested in trial NCT04818086?
The interventions under investigation include: Placebo (DRUG), Lemborexant (DRUG), Buprenorphine-naloxone (DRUG).
Who is sponsoring clinical trial NCT04818086?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.